As of 2025-07-03, the Relative Valuation of Akero Therapeutics Inc (AKRO) is (72.84) USD. This relative valuation is based on P/E multiples. With the latest stock price at 51.88 USD, the upside of Akero Therapeutics Inc based on Relative Valuation is -240.4%.
The range of the Relative Valuation is (59.01) - (81.59) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.9x - 24.1x | 20.0x |
| Forward P/E multiples | 17.5x - 28.7x | 23.1x |
| Fair Price | (59.01) - (81.59) | (72.84) |
| Upside | -213.8% - -257.3% | -240.4% |
| Date | P/E |
| 2025-07-01 | -15.21 |
| 2025-06-30 | -15.79 |
| 2025-06-27 | -16.62 |
| 2025-06-26 | -16.65 |
| 2025-06-25 | -16.28 |
| 2025-06-24 | -15.95 |
| 2025-06-23 | -15.99 |
| 2025-06-20 | -16.04 |
| 2025-06-18 | -16.24 |
| 2025-06-17 | -16.39 |
| 2025-06-16 | -16.49 |
| 2025-06-13 | -16.46 |
| 2025-06-12 | -15.85 |
| 2025-06-11 | -15.67 |
| 2025-06-10 | -16.13 |
| 2025-06-09 | -16.19 |
| 2025-06-06 | -16.06 |
| 2025-06-05 | -15.96 |
| 2025-06-04 | -15.68 |
| 2025-06-03 | -15.27 |
| 2025-06-02 | -15.01 |
| 2025-05-30 | -14.69 |
| 2025-05-29 | -14.21 |
| 2025-05-28 | -13.41 |
| 2025-05-27 | -13.61 |
| 2025-05-23 | -13.72 |
| 2025-05-22 | -14.49 |
| 2025-05-21 | -14.30 |
| 2025-05-20 | -14.07 |
| 2025-05-19 | -11.28 |
| 2025-05-16 | -11.50 |
| 2025-05-15 | -11.82 |
| 2025-05-14 | -11.21 |
| 2025-05-13 | -11.84 |
| 2025-05-12 | -12.29 |
| 2025-05-09 | -11.79 |
| 2025-05-08 | -12.54 |
| 2025-05-07 | -12.66 |
| 2025-05-06 | -12.43 |
| 2025-05-05 | -13.29 |
| 2025-05-02 | -13.28 |
| 2025-05-01 | -13.41 |
| 2025-04-30 | -13.49 |
| 2025-04-29 | -12.73 |
| 2025-04-28 | -12.48 |
| 2025-04-25 | -12.13 |
| 2025-04-24 | -12.13 |
| 2025-04-23 | -11.72 |
| 2025-04-22 | -11.39 |
| 2025-04-21 | -11.14 |